Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03664193 · ClinicalTrials.gov registry record · NA

MRI-guided Stereotactic Body Radiotherapy (SBRT) With Simultaneous Integrated Boost for Prostate Cancer

A NA study of Prostate Cancer, sponsored by Weill Medical College of Cornell University.

Completed
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT03664193 is a NA study of Prostate Cancer that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 30 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03664193, a NA study of Prostate Cancer, has completed, sponsored by Weill Medical College of Cornell University.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

Radiation is delivered to the prostate and seminal vesicles in 5 treatment sessions (fractions). Doses ranging from 35-45 Gy in 5 fractions have demonstrated good outcomes with acceptable toxicity.

Conditions Studied

Interventions

  • RADIATION SIBRT

Study Locations (1)

New York

  • Weill Cornell Medicine - New York

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2018-08-24
Est. Completion 2020-01-28
Phase NA

What the Registry Record Tells You About NCT03664193

The ClinicalTrials.gov registry entry for NCT03664193 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which SIBRT is the first listed.

NCT03664193 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT03664193 about?

NCT03664193 is a clinical study titled "MRI-guided Stereotactic Body Radiotherapy (SBRT) With Simultaneous Integrated Boost for Prostate Cancer". Radiation is delivered to the prostate and seminal vesicles in 5 treatment sessions (fractions). Doses ranging from 35-45 Gy in 5 fractions have demonstrated good outcomes with acceptable toxicity.

What is the current status of trial NCT03664193?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2018-08-24. Estimated completion is 2020-01-28.

What conditions does trial NCT03664193 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT03664193?

The interventions under investigation include: SIBRT (RADIATION).

Who is sponsoring clinical trial NCT03664193?

This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03664193 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.